AP2281A - Novel compounds. - Google Patents

Novel compounds.

Info

Publication number: AP2281A
Authority: AP; ARIPO
Prior art keywords: novel compounds; novel; compounds
Prior art date: 2005-03-25

Application number

AP2007004171A

Other languages

English (en)

Other versions

AP2007004171A0 (en

Inventor

James Francis Callahan

Zehong Wan

Hongxing Yan

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-03-25

Filing date

2006-03-24

Publication date

2011-10-31

2006-03-24 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2007-10-31 Publication of AP2007004171A0 publication Critical patent/AP2007004171A0/xx

2011-10-31 Application granted granted Critical

2011-10-31 Publication of AP2281A publication Critical patent/AP2281A/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Oncology (AREA)
Hematology (AREA)
Tropical Medicine & Parasitology (AREA)
Hospice & Palliative Care (AREA)
Ophthalmology & Optometry (AREA)
Communicable Diseases (AREA)
Obesity (AREA)
Psychiatry (AREA)
Transplantation (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)

AP2007004171A 2005-03-25 2006-03-24 Novel compounds. AP2281A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US66534705P	2005-03-25	2005-03-25
PCT/US2006/010792 WO2006104889A2 (en)	2005-03-25	2006-03-24	Novel compounds

Publications (2)

Publication Number	Publication Date
AP2007004171A0 AP2007004171A0 (en)	2007-10-31
AP2281A true AP2281A (en)	2011-10-31

Family

ID=37053936

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2007004171A AP2281A (en)	2005-03-25	2006-03-24	Novel compounds.

Country Status (23)

Country	Link
US (4)	US20090239846A1 (xx)
EP (1)	EP1866311A4 (xx)
JP (1)	JP2008535820A (xx)
KR (1)	KR20080005223A (xx)
CN (1)	CN101184758B (xx)
AP (1)	AP2281A (xx)
AR (1)	AR053450A1 (xx)
AU (1)	AU2006229967B2 (xx)
BR (1)	BRPI0609579A2 (xx)
CA (1)	CA2602546A1 (xx)
EA (1)	EA200702074A1 (xx)
IL (1)	IL185915A0 (xx)
MA (1)	MA29340B1 (xx)
MX (1)	MX2007011883A (xx)
NO (1)	NO20075273L (xx)
NZ (1)	NZ561438A (xx)
PE (2)	PE20061193A1 (xx)
SG (1)	SG166100A1 (xx)
TW (1)	TW200724142A (xx)
UA (1)	UA95230C2 (xx)
UY (1)	UY29439A1 (xx)
WO (1)	WO2006104889A2 (xx)
ZA (1)	ZA200707798B (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7235551B2 (en) *	2000-03-02	2007-06-26	Smithkline Beecham Corporation	1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
CN1847229B (zh)	2000-10-23	2011-05-04	史密丝克莱恩比彻姆公司	2，4，8-三取代-8H-吡啶并[2，3-d]嘧啶-7-酮化合物
EP2258687B1 (en)	2002-02-12	2012-12-26	Glaxosmithkline LLC	Nicotinamide derivates useful as P38 inhibitors
EP1499320B1 (en) *	2002-04-19	2007-08-22	Smithkline Beecham Corporation	Novel compounds
CN101495475A (zh) *	2005-03-25	2009-07-29	葛兰素集团有限公司	制备吡啶并[2,3-d]嘧啶-7-酮和3,4-二氢嘧啶并[4,5-d]嘧啶-2(1H)-酮衍生物的方法
PE20061193A1 (es) *	2005-03-25	2006-12-02	Glaxo Group Ltd	DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
UY29440A1 (es)	2005-03-25	2006-10-02	Glaxo Group Ltd	Nuevos compuestos
EP1868612A4 (en) *	2005-03-25	2010-03-24	Glaxo Group Ltd	NOVEL CONNECTIONS
JP2009542818A (ja) *	2006-06-16	2009-12-03	グラクソグループリミテッド	新規化合物
EP2034838A4 (en) *	2006-06-16	2012-01-04	Glaxo Group Ltd	NOVEL CONNECTIONS
WO2007147104A2 (en) *	2006-06-16	2007-12-21	Glaxo Group Limited	Novel compounds
CN101605760B (zh) *	2007-02-09	2012-06-20	陶氏益农公司	将某些取代的硫亚胺氧化为杀虫性磺基肟的方法
EP1992344A1 (en)	2007-05-18	2008-11-19	Institut Curie	P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
CA2726158A1 (en) *	2008-06-11	2009-12-17	Dana Farber Cancer Institute	Compounds and compositions useful for the treatment of malaria
CN103827118B (zh) *	2011-07-27	2016-03-09	葛兰素集团有限公司	双环嘧啶酮化合物
KR20200067170A (ko)	2017-10-05	2020-06-11	풀크럼 쎄러퓨틱스, 인코포레이티드	FSHD의 치료를 위하여 DUX4 및 하류 유전자 발현을 저감시키는 p38 키나제 저해제
US10342786B2 (en)	2017-10-05	2019-07-09	Fulcrum Therapeutics, Inc.	P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN111961034A (zh) *	2019-05-20	2020-11-20	浙江同源康医药股份有限公司	用作ret激酶抑制剂的化合物及其应用
CA3190461A1 (en) *	2020-09-16	2022-03-24	Young Jun Park	Pyrimido pyrimidinone compound and pharmaceutical composition comprising the same
CN113750095B (zh) *	2021-03-10	2023-07-04	中国医学科学院医药生物技术研究所	含有环丙基骨架的化合物在制备治疗和/或预防冠状病毒感染药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030100756A1 (en) *	2000-03-02	2003-05-29	Adams Jerry L	1,5- disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
US20060065703A1 (en) *	2004-09-29	2006-03-30	Debusk Patrick J	Carton with dispenser having access features

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA966134A (en) *	1972-05-05	1975-04-15	Haydn W.R. Williams	1,8-naphthyridine compounds
JPS5618982A (en) *	1979-06-14	1981-02-23	Wellcome Found	Pyrimidine derivatives and medicinal drug containing them
CY1308A (en)	1979-12-06	1985-12-06	Glaxo Group Ltd	Device for dispensing medicaments
US4353656A (en)	1980-10-14	1982-10-12	Xerox Corporation	Moving coil, multiple energy print hammer system including a closed loop servo
ATE23272T1 (de)	1981-07-08	1986-11-15	Draco Ab	Pulverinhalator.
GB2123831B (en)	1981-07-20	1986-01-15	Ciba Geigy Ag	Trisubstituted oxazo compounds
ES286422Y (es)	1982-10-08	1986-09-16	Glaxo Group Limited	Dispositivo para administrar medicamentos a pacientes
US4778054A (en)	1982-10-08	1988-10-18	Glaxo Group Limited	Pack for administering medicaments to patients
GB2169265B (en)	1982-10-08	1987-08-12	Glaxo Group Ltd	Pack for medicament
JPS60226882A (ja) *	1984-04-24	1985-11-12	Nippon Zoki Pharmaceut Co Ltd	新規ピリミドピリミジン誘導体
US4560691A (en) *	1984-07-13	1985-12-24	Sterling Drug Inc.	5-(Phenyl)-1,6-naphthyridin-2(1H)-ones, their cardiotonic use and preparation
SE8603252L (sv)	1985-07-30	1987-01-31	Glaxo Group Ltd	Anordning for att tillfora lekemedel till patienter
AU598093B2 (en)	1987-02-07	1990-06-14	Wellcome Foundation Limited, The	Pyridopyrimidines, methods for their preparation and pharmaceutical formulations thereof
JPH01261306A (ja)	1988-04-13	1989-10-18	Nippon Kayaku Co Ltd	２−アルキルチオ−４−アミノピリミジン誘導体を有効成分とする開花促進剤
GB9004781D0 (en)	1990-03-02	1990-04-25	Glaxo Group Ltd	Device
IE913473A1 (en) *	1990-10-15	1992-04-22	Fujisawa Pharmaceutical Co	Quinazoline derivatives and their preparation
WO1992012154A1 (en)	1990-12-31	1992-07-23	Fujisawa Pharmaceutical Co., Ltd.	Imidazotriazine derivatives
SG64322A1 (en) *	1991-05-10	1999-04-27	Rhone Poulenc Rorer Int	Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
IL102764A0 (en)	1991-08-16	1993-01-31	Merck & Co Inc	Quinazoline derivatives,and pharmaceutical compositions containing them
DE4131029A1 (de) *	1991-09-18	1993-07-29	Basf Ag	Substituierte pyrido (2,3-d) pyrimidine als antidots
GB9127376D0 (en)	1991-12-24	1992-02-19	Wellcome Found	Amidino derivatives
GB9303993D0 (en)	1993-02-26	1993-04-14	Fujisawa Pharmaceutical Co	New heterocyclic derivatives
US5466692A (en) *	1993-03-24	1995-11-14	American Home Products Corporation	Substituted pyridopyrimidines and antihypertensives
US5426110A (en) *	1993-10-06	1995-06-20	Eli Lilly And Company	Pyrimidinyl-glutamic acid derivatives
GB9325217D0 (en)	1993-12-09	1994-02-09	Zeneca Ltd	Pyrimidine derivatives
IL112249A (en)	1994-01-25	2001-11-25	Warner Lambert Co	Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5547954A (en) *	1994-05-26	1996-08-20	Fmc Corporation	2,4-Diamino-5,6-disubstituted-and 5,6,7-trisubstituted-5-deazapteridines as insecticides
TW574214B (en)	1994-06-08	2004-02-01	Pfizer	Corticotropin releasing factor antagonists
ATE191470T1 (de)	1994-06-15	2000-04-15	Wellcome Found	Enzymhemmer
EP0779292A4 (en) *	1994-08-29	1997-09-24	Yamanouchi Pharma Co Ltd	NEW NAPHTHYRIDE DERIVATIVES AND MEDICAL COMPOSITIONS CONTAINING THEM
IL115256A0 (en) *	1994-11-14	1995-12-31	Warner Lambert Co	6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
AU698364B2 (en)	1995-03-10	1998-10-29	Minnesota Mining And Manufacturing Company	Aerosol valves
US5620981A (en) *	1995-05-03	1997-04-15	Warner-Lambert Company	Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
US5760220A (en) *	1995-06-07	1998-06-02	American Home Products Corporation	Process for preparation of biphenyl derivatives
US5767097A (en) *	1996-01-23	1998-06-16	Icn Pharmaceuticals, Inc.	Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
DE69718306D1 (de)	1996-04-12	2003-02-13	Sumitomo Pharma	Piperidinylpyrimidine derivate
ZA973884B (en) *	1996-05-23	1998-11-06	Du Pont Merck Pharma	Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
US6875769B2 (en) *	1996-05-23	2005-04-05	Pfizer Inc.	Substituted6,6-hetero-bicyclicderivatives
PL331602A1 (en)	1996-08-06	1999-08-02	Pfizer	Pyrido- or pyrimido-substituted 6,6- or 6,7-bicyclic derivatives
TW477787B (en)	1996-08-27	2002-03-01	Pfizer	Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
US6509320B1 (en) *	1996-10-16	2003-01-21	Icn Pharmaceuticals, Inc.	Purine L-nucleosides, analogs and uses thereof
US6147080A (en)	1996-12-18	2000-11-14	Vertex Pharmaceuticals Incorporated	Inhibitors of p38
GB9700226D0 (en)	1997-01-08	1997-02-26	Glaxo Group Ltd	Inhalation device
MY117948A (en)	1997-01-13	2004-08-30	Glaxo Group Ltd	Nitride oxide synthase inhibitors.
US5945422A (en) *	1997-02-05	1999-08-31	Warner-Lambert Company	N-oxides of amino containing pyrido 2,3-D! pyrimidines
US6498163B1 (en) *	1997-02-05	2002-12-24	Warner-Lambert Company	Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
KR20000070751A (ko)	1997-02-05	2000-11-25	로즈 암스트롱, 크리스틴 에이. 트러트웨인	세포 증식 억제제로서의 피리도[2,3-ｄ]피리미딘 및 4-아미노피리미딘
DE19723722A1 (de)	1997-05-30	1998-12-10	Schering Ag	Nichtsteroidale Gestagene
EP1037639A4 (en)	1997-12-19	2002-04-17	Smithkline Beecham Corp	HETEROARYL-SUBSTITUTED IMIDAZOLE COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES
US6506766B1 (en)	1998-02-13	2003-01-14	Abbott Laboratories	Glucocortiocoid-selective antinflammatory agents
IL137922A0 (en)	1998-02-17	2001-10-31	Tularik Inc	Anti-viral pyrimidine derivatives
JP2000038350A (ja)	1998-05-18	2000-02-08	Yoshitomi Pharmaceut Ind Ltd	糖尿病治療薬
KR20010043829A (ko)	1998-05-26	2001-05-25	로즈 암스트롱, 크리스틴 에이. 트러트웨인	세포 증식 억제제로서의 비시클릭 피리미딘 및 비시클릭3,4-디히드로피리미딘
US6248225B1 (en) *	1998-05-26	2001-06-19	Ppg Industries Ohio, Inc.	Process for forming a two-coat electrodeposited composite coating the composite coating and chip resistant electrodeposited coating composition
GB9811599D0 (en)	1998-05-30	1998-07-29	Glaxo Group Ltd	Nitric oxide synthase inhibitors
JP2002517486A (ja) *	1998-06-12	2002-06-18	バーテックスファーマシューティカルズインコーポレイテッド	ｐ３８のインヒビター
US6184226B1 (en) *	1998-08-28	2001-02-06	Scios Inc.	Quinazoline derivatives as inhibitors of P-38 α
EP1117653B1 (en) *	1998-10-01	2003-02-05	AstraZeneca AB	Quinoline and quinazoline derivatives and their use as inhibitors of cytokine mediated diseases
WO2000023444A1 (en)	1998-10-21	2000-04-27	Abbott Laboratories	5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
US6358959B1 (en)	1999-01-26	2002-03-19	Merck & Co., Inc.	Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists
CN1353717A (zh)	1999-05-04	2002-06-12	莱加制药公司	四环黄体酮受体调节剂化合物及其方法
CO5180649A1 (es)	1999-09-01	2002-07-30	Abbott Lab	Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes
AU7491400A (en)	1999-09-17	2001-04-17	Abbott Gmbh & Co. Kg	Kinase inhibitors as therapeutic agents
WO2001042243A2 (en)	1999-12-08	2001-06-14	Advanced Medicine, Inc.	Protein kinase inhibitors
US6632666B2 (en)	2000-01-14	2003-10-14	Biolife Solutions, Inc.	Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
PE20011066A1 (es)	2000-01-25	2001-10-22	Warner Lambert Co	PIRIDO [2,3-d] PIRIMIDIN-2,7-DIAMINAS INHIBIDORES DE CINASAS
CN1433417A (zh) *	2000-01-27	2003-07-30	沃尼尔·朗伯公司	用于治疗神经变性疾病的吡啶并嘧啶酮衍生物
BR0109056A (pt)	2000-03-06	2003-06-03	Warner Lambert Co	Inibidores da cinase de tirosina de 5-alquilpirido[2,3-d]pirimidinas
KR20040041082A (ko) *	2000-07-24	2004-05-13	비브콤 인코포레이티드	멀티미디어 북마크와 비디오의 가상 편집을 위한 시스템및 방법
NZ525056A (en)	2000-09-29	2004-11-26	Glaxo Group Ltd	Morpholin-acetamide derivatives for the treatment of inflammatory diseases
AU2002248269A1 (en)	2000-10-19	2002-08-12	Smithkline Beecham Corporation	Use of p38 inhibitors for the treatment of inflammation-enhanced cough
CN1847229B (zh) *	2000-10-23	2011-05-04	史密丝克莱恩比彻姆公司	2，4，8-三取代-8H-吡啶并[2，3-d]嘧啶-7-酮化合物
WO2002058695A1 (en)	2000-12-20	2002-08-01	Merck & Co., Inc.	(halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents
GB0031179D0 (en)	2000-12-21	2001-01-31	Glaxo Group Ltd	Nitric oxide synthase inhibitors
US6484903B2 (en)	2001-01-09	2002-11-26	Riverwood International Corporation	Carton with an improved dispensing feature in combination with a unique handle
PE20030008A1 (es)	2001-06-19	2003-01-22	Bristol Myers Squibb Co	Inhibidores duales de pde 7 y pde 4
WO2003010143A1 (en)	2001-07-26	2003-02-06	Samsung Electronics Co., Ltd.	Dialkylhydroxybenzoic acid derivatives containing metal chelating groups and their therapeutic uses
JP4178783B2 (ja)	2001-10-19	2008-11-12	三菱化学株式会社	光学記録媒体
US7019002B2 (en) *	2001-12-11	2006-03-28	Pharmacia & Upjohn, S.P.A.	Pyridopyrimidinones derivatives as telomerase inhibitors
JP2005519897A (ja)	2002-01-14	2005-07-07	ベーリンガーインゲルハイムファーマシューティカルズインコーポレイテッド	グルココルチコイドミメチックス、その製造方法、それを含む医薬製剤及びその使用
WO2003061651A1 (en)	2002-01-22	2003-07-31	The Regents Of The University Of California	Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
ES2251677T3 (es) *	2002-01-22	2006-05-01	Warner-Lambert Company Llc	2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas.
US7268152B2 (en)	2002-03-26	2007-09-11	Boehringer Ingelheim Pharmaceuticals, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
KR101022977B1 (ko)	2002-03-26	2011-03-18	베링거 인겔하임 파마슈티칼즈, 인코포레이티드	글루코코르티코이드 모사체, 이의 제조방법, 약제학적조성물 및 이의 용도
DE10215316C1 (de)	2002-04-02	2003-12-18	Schering Ag	Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
US7282591B2 (en)	2002-04-11	2007-10-16	Merck & Co., Inc.	1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators
NZ536123A (en) *	2002-05-06	2006-09-29	Genelabs Tech Inc	Nucleoside derivatives for treating hepatitis C virus infection
US7186864B2 (en)	2002-05-29	2007-03-06	Boehringer Ingelheim Pharmaceuticals, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en)	2002-06-06	2006-07-11	Boehringer Ingelheim Pharmaceuticals, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
BR0312575A (pt)	2002-07-08	2005-05-03	Pfizer Prod Inc	Moduladores do receptor de glicocorticóides
US7442554B2 (en)	2002-07-18	2008-10-28	Bristol-Myers Squibb Company	Compositions and methods involving glucocorticoid receptor site II
AU2003251970A1 (en)	2002-07-18	2004-02-09	Bristol-Myers Squibb Company	Modulators of the glucocorticoid receptor and method
DE60322713D1 (de)	2002-08-21	2008-09-18	Boehringer Ingelheim Pharma	Substituierte dihydrochinoline als glucocorticoid-mmimetika,verfahren zu deren herstellung, pharmazeutische zubereitungen und deren verwendung
JP4520309B2 (ja)	2002-09-20	2010-08-04	メルク・シャープ・エンド・ドーム・コーポレイション	選択的糖質コルチコイド受容体調節剤としてのオクタヒドロ−２−Ｈ−ナフト［１，２−ｆ］インドール−４−カルボキサミド誘導体
WO2004043367A2 (en) *	2002-11-06	2004-05-27	Bristol-Myers Squibb Company	Fused heterocyclic compounds and use thereof
JP2004203751A (ja)	2002-12-24	2004-07-22	Pfizer Inc	置換６，６−ヘテロ二環式誘導体
DE602004021558D1 (de) *	2003-01-17	2009-07-30	Warner Lambert Co	2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
JP2006517976A (ja)	2003-02-14	2006-08-03	スミスクライン・ビーチャム・コーポレイション	新規化合物
US7138412B2 (en) *	2003-03-11	2006-11-21	Bristol-Myers Squibb Company	Tetrahydroquinoline derivatives useful as serine protease inhibitors
CA2527017A1 (en) *	2003-05-27	2004-12-09	Pfizer Products Inc.	Quinazolines and pyrido [3,4-d] pyrimidines as receptor tyrosine kinase inhibitors
TWI220897B (en) *	2003-07-22	2004-09-11	Benq Corp	Recording media feeding system and method
JP4808156B2 (ja)	2003-08-05	2011-11-02	バーテックスファーマシューティカルズインコーポレイテッド	電位依存型イオンチャネルの阻害剤としての縮合ピリミジン化合物
US7098222B2 (en) *	2004-05-12	2006-08-29	Abbott Laboratories	Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
EP1828186A1 (en) *	2004-12-13	2007-09-05	Sunesis Pharmaceuticals, Inc.	Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
EP1868612A4 (en) *	2005-03-25	2010-03-24	Glaxo Group Ltd	NOVEL CONNECTIONS
UY29440A1 (es) *	2005-03-25	2006-10-02	Glaxo Group Ltd	Nuevos compuestos
PE20061193A1 (es) *	2005-03-25	2006-12-02	Glaxo Group Ltd	DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
CN101495475A (zh) *	2005-03-25	2009-07-29	葛兰素集团有限公司	制备吡啶并[2,3-d]嘧啶-7-酮和3,4-二氢嘧啶并[4,5-d]嘧啶-2(1H)-酮衍生物的方法

2006
- 2006-03-23 PE PE2006000331A patent/PE20061193A1/es not_active Application Discontinuation
- 2006-03-23 UY UY29439A patent/UY29439A1/es unknown
- 2006-03-23 PE PE2010000198A patent/PE20100741A1/es not_active Application Discontinuation
- 2006-03-23 TW TW095109982A patent/TW200724142A/zh unknown
- 2006-03-23 AR ARP060101148A patent/AR053450A1/es not_active Application Discontinuation
- 2006-03-24 AP AP2007004171A patent/AP2281A/xx active
- 2006-03-24 KR KR1020077024433A patent/KR20080005223A/ko not_active Ceased
- 2006-03-24 US US11/908,435 patent/US20090239846A1/en not_active Abandoned
- 2006-03-24 CN CN2006800183985A patent/CN101184758B/zh not_active Expired - Fee Related
- 2006-03-24 JP JP2008503226A patent/JP2008535820A/ja active Pending
- 2006-03-24 EA EA200702074A patent/EA200702074A1/ru unknown
- 2006-03-24 UA UAA200710644A patent/UA95230C2/ru unknown
- 2006-03-24 AU AU2006229967A patent/AU2006229967B2/en not_active Ceased
- 2006-03-24 US US11/389,112 patent/US7674789B2/en not_active Expired - Fee Related
- 2006-03-24 NZ NZ561438A patent/NZ561438A/en not_active IP Right Cessation
- 2006-03-24 CA CA002602546A patent/CA2602546A1/en not_active Abandoned
- 2006-03-24 SG SG201006926-8A patent/SG166100A1/en unknown
- 2006-03-24 WO PCT/US2006/010792 patent/WO2006104889A2/en not_active Ceased
- 2006-03-24 BR BRPI0609579-8A patent/BRPI0609579A2/pt not_active IP Right Cessation
- 2006-03-24 EP EP06748656A patent/EP1866311A4/en not_active Withdrawn
- 2006-03-24 MX MX2007011883A patent/MX2007011883A/es active IP Right Grant
2007
- 2007-09-11 IL IL185915A patent/IL185915A0/en unknown
- 2007-09-12 ZA ZA200707798A patent/ZA200707798B/xx unknown
- 2007-09-24 MA MA30236A patent/MA29340B1/fr unknown
- 2007-10-15 NO NO20075273A patent/NO20075273L/no not_active Application Discontinuation
2009
- 2009-11-16 US US12/618,927 patent/US20100093765A1/en not_active Abandoned
- 2009-11-16 US US12/618,933 patent/US20100093766A1/en not_active Abandoned

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030100756A1 (en) *	2000-03-02	2003-05-29	Adams Jerry L	1,5- disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
US20060065703A1 (en) *	2004-09-29	2006-03-30	Debusk Patrick J	Carton with dispenser having access features

Also Published As

Publication number	Publication date
IL185915A0 (en)	2008-01-06
EP1866311A2 (en)	2007-12-19
UY29439A1 (es)	2006-10-02
CA2602546A1 (en)	2006-10-05
EA200702074A1 (ru)	2008-02-28
CN101184758B (zh)	2012-05-02
MX2007011883A (es)	2007-11-13
WO2006104889A2 (en)	2006-10-05
CN101184758A (zh)	2008-05-21
PE20061193A1 (es)	2006-12-02
JP2008535820A (ja)	2008-09-04
NZ561438A (en)	2011-02-25
US7674789B2 (en)	2010-03-09
US20100093765A1 (en)	2010-04-15
KR20080005223A (ko)	2008-01-10
TW200724142A (en)	2007-07-01
BRPI0609579A2 (pt)	2010-04-20
AR053450A1 (es)	2007-05-09
SG166100A1 (en)	2010-11-29
US20100093766A1 (en)	2010-04-15
NO20075273L (no)	2007-12-12
PE20100741A1 (es)	2010-11-25
EP1866311A4 (en)	2010-03-31
AU2006229967A1 (en)	2006-10-05
AP2007004171A0 (en)	2007-10-31
US20060235030A1 (en)	2006-10-19
AU2006229967B2 (en)	2012-02-09
UA95230C2 (ru)	2011-07-25
US20090239846A1 (en)	2009-09-24
MA29340B1 (fr)	2008-03-03
WO2006104889A3 (en)	2007-04-12
ZA200707798B (en)	2009-08-26

Publication	Publication Date	Title
ZA200707798B (en)	2009-08-26	Novel compounds
ZA200707564B (en)	2008-10-29	Novel Compounds
EP1868612A4 (en)	2010-03-24	NOVEL CONNECTIONS
AP2337A (en)	2011-12-14	Motilide compounds.
GB0503955D0 (en)	2005-04-06	Novel compounds
GB0516464D0 (en)	2005-09-14	Novel compounds
GB0517886D0 (en)	2005-10-12	Novel compounds
EP1869026A4 (en)	2009-12-23	NEW CONNECTIONS
GB0500140D0 (en)	2005-02-16	Novel compounds
GB0500919D0 (en)	2005-02-23	Novel compounds
GB0500406D0 (en)	2005-02-16	Novel compounds
GB0501961D0 (en)	2005-03-09	Novel compounds
GB0501959D0 (en)	2005-03-09	Novel compounds
GB0501094D0 (en)	2005-02-23	Novel compounds
GB0500925D0 (en)	2005-02-23	Novel compounds
GB0500923D0 (en)	2005-02-23	Novel compounds
GB0500921D0 (en)	2005-02-23	Novel compounds
GB0503121D0 (en)	2005-03-23	Novel compounds
GB0503122D0 (en)	2005-03-23	Novel compounds
GB0500920D0 (en)	2005-02-23	Novel compounds
GB0503126D0 (en)	2005-03-23	Novel compounds
GB0500916D0 (en)	2005-02-23	Novel compounds
GB0500887D0 (en)	2005-02-23	Novel compounds
GB0500886D0 (en)	2005-02-23	Novel compounds
GB0500885D0 (en)	2005-02-23	Novel compounds